**Core tip:** In this study, we found that lymphatic and/or blood vessel invasion (LBVI) + status was associated with Borrmann type IV, low histological grade, large tumor size, and advanced pT and pN status. The 5-year survival rate of LBVI+ patients was significantly lower than that of LBVI-- patients. No significant difference was observed in the prognosis of Borrmann type III/LBVI+ disease and Borrmann type IV disease. Therefore, we proposed a revised Borrmann type IV (r-Bor IV) as Borrmann type III plus LBVI+, and found that r-Bor IV was associated with poor prognosis in patients with advanced proximal gastric cancer, which outweighed the prognostic significance of pT status.

INTRODUCTION
============

Gastric cancer is a significant public health problem and is associated with substantial rates of morbidity and mortality\[[@B1],[@B2]\]. Although radical D2 gastrectomy is the main treatment for gastric cancer, the high incidence of recurrence and metastasis postoperatively leads to a high mortality rate, even after curative resection\[[@B3]-[@B5]\]. Proximal-third gastric cancers (PGCs) have a poorer prognosis than distal gastric cancers, as they are characterized by a more aggressive biological behavior and are typically diagnosed at an advanced stage\[[@B6]-[@B8]\]. Furthermore, although the overall incidence of gastric cancer has decreased, the incidence of PGC has increased in recent decades\[[@B9]\]. Therefore, it is important to identify prognostic factors for PGC and to adopt more aggressive adjuvant treatment strategies, particularly for patients with advanced PGC (APGC).

Lymphatic and/or blood vessel invasion (LBVI) is defined as the presence of tumor cells in the lymphovascular system or in the small veins of tumor tissue, under microscope. In addition, LBVI plays an important role in tumor cell dissemination and metastasis during progression, which contributes to the poor prognosis of patients with gastric cancer\[[@B10]-[@B12]\]. The Borrmann classification system is used to describe the macroscopic appearance of advanced gastric cancer, and Borrmann type IV gastric cancer is independently associated with poor prognosis. Moreover, Borrmann type IV is more likely to be diagnosed in patients with PGC than in patients with distal gastric cancers\[[@B13]-[@B15]\]. However, few studies have examined the prognostic significance of LBVI status combined with Borrmann type in patients with APGC. Therefore, in this retrospective study, the clinicopathological characteristics of APGC patients with LBVI (LBVI+) or without LBVI (LBVI--) were compared, and LBVI status was examined to determine whether it could be used to further enhance the Borrmann classification system.

MATERIALS AND METHODS
=====================

Patients
--------

All patients underwent curative proximal or total gastrectomy with standard lymph node dissection at the First Affiliated Hospital of the China Medical University between January 2005 and October 2012. A total of 494 patients with APGC and complete clinicopathological and surgical data, including age, sex, tumor size, Borrmann classification, LBVI status, pT status, pN status, histological grade, resection type, and extent of resection, were included in this study. We defined APGC as: (1) A tumor located at the proximal third of the stomach, including the gastric cardia, esophageal-gastric junction, and fundus; (2) A tumor histologically diagnosed as gastric adenocarcinoma; and (3) A tumor with a depth of invasion beyond the mucous layer. We excluded the following patients: (1) Those with distant metastasis, peritoneal dissemination, or pathological T4b stage; (2) Those who underwent palliative surgery; (3) Those who died due to postoperative non-tumor-related events; (4) Those who had undergone preoperative chemotherapy or radiotherapy; (5) Those with carcinoma in the remnant stomach; and (6) Those who were lost to follow-up. Therefore, 440 patients were included in the final analyses.

All patients underwent standardized follow-up every 3 mo for the first 2 years after surgery, every 6 mo during the third year, and annually thereafter. The follow-up period was from surgery until the patient's death or October 2017. The median follow-up period was 65 mo (range: 2--122 mo).

Tumor classification
--------------------

All resected specimens were fixed using 10% formalin, dehydrated using ethanol, embedded in paraffin, stained with hematoxylin and eosin (HE), and evaluated using an optical microscope. Each patient's LBVI status and Borrmann type were independently evaluated by two pathologists, and disagreements were resolved by a third pathologist. The Borrmann classification and LBVI status were determined based on the Japanese Classification of Gastric Carcinoma\[[@B16]\]. Borrmann type I (limited mass) was defined as a tumor that protruded toward the gastric lumen and had a distinct border separating it from the surrounding mucosa. Borrmann type II (limited ulcerative) was defined as an ulcerated tumor with its dam-shaped margin protruding and surrounded by a thickened gastric wall with clear margins. Borrmann type III (infiltrative ulcerative) was defined as a Borrmann type II tumor that was surrounded by a thickened gastric wall without clear margins. Borrmann type IV (diffuse infiltrative) was defined as a tumor with diffuse infiltration through each layer of the gastric wall, without marked ulceration or raised margins, and without clear margins separating the tumor from normal tissue. The presence of LBVI was identified based on the presence of tumor cells in the lymphovascular system or in the small veins of tumor tissue. Pathological tumor staging was based on the TNM system of the American Joint Committee on Cancer and the International Union Against Cancer (eighth edition).

Statistical analysis
--------------------

Differences between the LBVI-- and LBVI+ groups were evaluated using the Chi-square test for categorical variables and the independent *t* test for continuous variables. The Kaplan-Meier method and log-rank test were used to identify univariate differences in survival. A multivariate analysis was performed using the Cox proportional hazards model. All statistical analyses were performed using SPSS software (version 22.0; IBM Corp., Armonk, NY, USA), and differences were considered statistically significant at two-sided *P* values of \< 0.05.

RESULTS
=======

Clinicopathological characteristics
-----------------------------------

Of the 440 eligible patients with APGC, 97 patients (22.1%) underwent proximal gastrectomy and 343 patients (77.9%) underwent total gastrectomy. All patients achieved radical resection (R0), and D2 lymphadenectomy was performed in 436 patients (98.2%). Among the 440 patients, 151 (34.3%) had LBVI and 72 (16.4%) had Borrmann type IV disease. The incidence of LBVI+ was 15.5% (9/58) in Borrmann type I--II disease, 35.8% (111/310) in Borrmann type III disease, and 43.1% (31/72) in Borrmann type IV disease.

Table [1](#T1){ref-type="table"} shows the patients' clinicopathological characteristics according to LBVI status. The presence of LVBI was significantly associated with Borrmann type IV (*P* = 0.003), low histological grade (*P* = 0.001), large tumor size (*P* = 0.013), advanced pT status (*P* = 0.002), and advanced pN status (*P* \< 0.001).

###### 

Clinicopatholgical factors according to lymphatic vessel invasion, *n* (%)

  **Variable**                                              ***n***      **Lymphatic vessel invasion**   ***P* value**    
  --------------------------------------------------------- ------------ ------------------------------- ---------------- -------
  Age (yr)                                                  440          59.86 ± 10.4                    58.55 ± 11.128   0.426
  Gender                                                                                                                  0.765
  Male                                                      333 (75.7)   220 (66.1)                      113 (33.9)       
  Female                                                    107 (24.3)   69 (64.5)                       38 (35.5)        
  Tumor size (cm)                                                                                                         0.013
  ≤ 5                                                       169 (38.5)   123 (72.8)                      46 (27.2)        
  \> 5                                                      231 (52.5)   166 (60.4)                      105 (39.6)       
  Macroscopic type                                                                                                        0.003
  Borrmann I-II                                             58 (13.2)    49 (84.5)                       9 (15.5)         
  Borrmann III                                              310 (70.4)   199 (64.2)                      111 (35.8)       
  Borrmann IV                                               72 (16.4)    41 (56.9)                       31 (43.1)        
  Adjacent organs invaded[1](#T1FN1){ref-type="table-fn"}                                                                 0.815
  With                                                      105 (23.9)   70 (66.7)                       36 (33.3)        
  Without                                                   335 (76.1)   219 (65.4)                      116 (34.6)       
  Histologic grade                                                                                                        0.001
  Well                                                      203 (46.1)   149 (73.4)                      54 (26.6)        
  Poor                                                      237 (53.9)   140 (59.1)                      97 (40.9)        
  AJCC pT category                                                                                                        0.002
  pT2                                                       53 (12.0)    37 (69.8)                       16 (30.2)        
  pT3                                                       136 (31.0)   104 (76.5)                      32 (23.5)        
  pT4a                                                      251 (57.0)   148 (59.0)                      103 (41.0)       
  AJCC pN category                                                                                                        0.000
  pN0                                                       102 (23.2)   96 (94.1)                       6 (5.9)          
  pN1                                                       71 (16.2)    51 (71.8)                       20 (28.2)        
  pN2                                                       98 (22.2)    65 (66.3)                       33 (33.7)        
  pN3a                                                      89 (20.2)    47 (52.8)                       42 (47.2)        
  pN3b                                                      80 (18.2)    30 (37.5)                       50 (62.5)        
  Resection type                                                                                                          0.426
  Proximal                                                  97 (22.1)    67 (69.1)                       30 (30.1)        
  Total                                                     343 (77.9)   222 (64.7)                      121 (35.3)       
  Combined other organ resection                                         0.815                                            
  No                                                        396 (90.0)   259 (65.4)                      137 (34.6)       
  Yes                                                       44 (10.0)    30 (68.2)                       14 (31.8)        
  Survival at 5 yr                                          34.2%        42.5%                           25.1%            0.000

Adjacent organs invaded were diagnosed by the surgeon intraoperatively.

Predicting APGC prognosis after curative resection
--------------------------------------------------

In the univariate survival analyses, the 5-year overall survival rate of LBVI+ patients was significantly lower than that of LBVI-- patients (19.1% *vs* 25.1%, *P* \< 0.001; Figure [1A](#F1){ref-type="fig"}). In addition, significant differences in the 5-year survival rates were observed when patients with Borrmann type I--II (59.4%), type III (34.3%), and type IV disease (13.4%) were compared (*P* \< 0.001; Figure [1B](#F1){ref-type="fig"}). Multivariate Cox regression analysis revealed that poor survival was independently associated with lymph node metastasis (*P* \< 0.001), Borrmann type IV (*P* = 0.016), and invasion of adjacent organs (*P* = 0.015), but was not independently associated with LBVI+ status (*P* = 0.197) or advanced pT status (*P* = 0.996; Table [2](#T2){ref-type="table"}).

![Survival according to lymphatic and/or blood vessel invasion status and Borrmann type. Survival curves according to, A: Lymphatic and/or blood vessel invasion status; B: Borrmann type (Bor) in 440 patients with advanced proximal gastric cancer.](WJGO-11-642-g001){#F1}

###### 

Univariate and multivariate analysis of prognostic factors in 440 patients with advanced proximal gastric cancer after curative resection

                                                            **Univariate analysis**   **Multivariate analysis**                         
  --------------------------------------------------------- ------------------------- --------------------------- --------------------- -------
  Age (yr)                                                                                                                              
  \> 60 *vs* ≤ 60                                           1.295 (1.031-1.628)       0.026                       1.206 (0.928-1.567)   0.161
  Tumor size (cm)                                                                                                                       
  \> 5 *vs* ≤ 5                                             2.118 (1.648-2.722)       0.000                       1.246 (0.922-1.684)   0.153
  Adjacent organs invaded[1](#T2FN1){ref-type="table-fn"}                                                                               
  With vs Without                                           1.630 (1.264-2.102)       0.000                       1.436 (1.074-1.919)   0.015
  Histologic differentiation                                                                                                            
  Poor vs well                                              1.370 (1.088-1.725)       0.007                       1.278 (0.980-1.666)   0.070
  AJCC pT category                                                                                                                      0.996
  pT3 vs pT2                                                1.707 (1.093-2.666)       0.019                       1.019 (0.604-1.718)   0.943
  pT4a vs pT2                                               2.405 (1.582-3.656)       0.000                       1.024 (0.614-1.707)   0.927
  AJCC pN category                                                                                                                      0.000
  pN1 vs pN0                                                1.758 (1.110-2.783)       0.016                       1.487 (0.878-2.517)   0.140
  pN2 vs pN0                                                2.996 (1.995-4.500)       0.000                       2.501 (1.567-3.990)   0.000
  pN3a vs pN0                                               4.531 (3.034-6.765)       0.000                       3.406 (2.106-5.509)   0.000
  pN3b vs pN0                                               6.377 (4.240-9.592)       0.000                       4.245 (2.551-7.064)   0.000
  Resection type                                                                                                                        
  Total vs Proximal                                         1.772 (1.279-2.456)       0.001                       1.103 (0.773-1.578)   0.590
  Combined other organ resection                                                                                                        
  Yes vs No                                                 1.579 (1.109-2.248)       0.011                       1.189 (0.812-1.740)   0.374
  LBVI                                                                                                                                  
  Positive vs Negative                                      1.750 (1.387-2.207)       0.000                       1.200 (0.910-1.583)   0.197
  Borrmann classification                                                                                                               0.019
  Bor III vs Bor I-II                                       2.016 (1.321-3.077)       0.001                       1.273 (0.807-2.006)   0.299
  Bor IV vs Bor I-II                                        3.686 (2.295-5.922)       0.000                       1.935 (1.131-3.311)   0.016

Adjacent organs invaded were diagnosed by the surgeon intraoperatively.

Prognostic significance of LBVI status in the Borrmann classification system
----------------------------------------------------------------------------

Borrmann type III or IV disease was present in 382 of the 440 patients with APGC (86.8%), and the prognostic significance of LBVI status in this subgroup was evaluated. Among the patients with Borrmann type III disease, LBVI+ status was associated with significantly poorer survival (5-year survival: 19.8% *vs* 43.1%, *P* \< 0.001; Figure [2A](#F2){ref-type="fig"}). However, no significant difference in survival was observed according to LBVI status in patients with Borrmann type IV disease (5-year survival: 13.0% *vs* 13.7%, *P* = 0.571; Figure [2B](#F2){ref-type="fig"}). Patients with LBVI+ and Borrmann type III disease had a similar prognosis to patients with LBVI-- and Borrmann type IV disease (5-year survival: 19.8% *vs* 13.7%, *P* = 0.293; Figure [2C](#F2){ref-type="fig"}) and to patients with LBVI+ and Borrmann type IV disease (5-year survival: 19.8% *vs* 12.9%, *P* = 0.121; Figure [2D](#F2){ref-type="fig"}).

![Survival after incorporating lymphatic and/or blood vessel invasion into the Borrmann type. Survival curves after incorporating lymphatic and/or blood vessel invasion into the Borrmann type (Bor) for 382 patients with infiltrative advanced proximal gastric cancer (Bor III and IV).](WJGO-11-642-g002){#F2}

Based on these results, we proposed revised versions of Borrmann type III (r-Bor III) as Borrmann type III and LBVI-- and type IV (r-Bor IV) as Borrmann type III plus LBVI+ or Borrmann type IV. Figure [3](#F3){ref-type="fig"} shows that patients with r-Bor IV APGC had a significantly poorer prognosis based on the univariate analysis (*P* \< 0.001) and multivariate analysis (hazard ratio: 1.861, 95% CI: 1.091-3.714, *P* = 0.02).

![Prognostic significance of revised Borrmann type III and type IV. Prognostic significance of revised Borrmann type III (r-Bor III) and type IV (r-Bor IV) in 440 patients with advanced proximal gastric cancer according to the A) univariate analysis and B) multivariate analysis.](WJGO-11-642-g003){#F3}

Prognostic significance of r-Bor III and r-Bor IV in pT3 and pT4a APGC
----------------------------------------------------------------------

We further examined our r-Bor III and r-Bor IV subgroups to identify survival differences after radical surgery according to pT3 and pT4a status. Patients with pT3 and r-Bor IV disease had a significantly poorer prognosis than patients with pT3 and r-Bor III disease (*P* = 0.002; Figure [4A](#F4){ref-type="fig"}) and those with pT4a disease (*P* \< 0.001; Figure [4B](#F4){ref-type="fig"}). Moreover, patients with pT3 and r-Bor IV disease had a significantly poorer prognosis than patients with pT4a and r-Bor III disease (*P* = 0.023; Figure [4C](#F4){ref-type="fig"}). No significant differences in prognosis were observed when we compared pT3 and pT4a status in patients with r-Bor III disease (*P* = 0.249; Figure [4D](#F4){ref-type="fig"}), or when we compared pT3 and pT4a status in patients with r-Bor IV disease (*P* = 0.588; Figure [4D](#F4){ref-type="fig"}).

![Prognostic significance of revised Borrmann type III and type IV. Prognostic significance of revised Borrmann type III (r-Bor III) and type IV (r-Bor IV) in patients with pT3 and pT4a disease.](WJGO-11-642-g004){#F4}

DISCUSSION
==========

Compared to patients with distal gastric cancer, patients with APGC are more likely to have adverse clinicopathological characteristics that affect their prognosis, such as lymph node metastasis, serosa invasion, LBVI+ status, and larger tumor size\[[@B8],[@B17]\]. The multivariate analysis in the present study confirmed that lymph node metastasis, Borrmann type IV, and invasion of adjacent organs were independent risk factors for patients with APGC. The present study also revealed that LBVI+ status was related to poor prognosis in this setting, although it was not an independent prognostic factor. Previous studies revealed that LBVI+ status is associated with poor prognosis after radical surgery for gastric cancer, and is an independent predictor of poor prognosis in patients with negative lymph nodes\[[@B18]-[@B20]\].

The Borrmann classification is generally assigned based on macroscopic examination of the tumor, although some Borrmann type III tumors have a similar appearance and prognosis to Borrmann type IV tumors, which has led to the term "limited Borrmann type IV"\[[@B21]\]. Previous studies have indicated that Borrmann type IV disease has a very poor prognosis\[[@B22],[@B23]\], and we also found that Borrmann type IV disease was an independent prognostic factor in APGC patients (5-year survival: 13.3%). We incorporated LBVI in an attempt to better differentiate Borrmann type III and IV disease, which revealed that patients with r-Bor IV disease had a similar prognosis to those with Borrmann type IV disease, but had significantly poorer prognosis than patients with r-Bor III disease. Thus, LBVI status can help differentiate "limited Borrmann type IV" from standard Borrmann type III. Interestingly, some studies have reported a lower rate of liver metastasis after surgical resection in Borrmann type IV patients than in Borrmann type III patients, which raises the question of whether LBVI might also be useful in that setting. Further studies are needed to examine this hypothesis.

Although pT status is not an independent prognostic factor for APGC, it is an important factor that influences the prognosis of advanced gastric cancer. In this context, pT1 and pT2 tumors are generally smaller and more accurately classified in a comprehensive pathological examination, while pT3 and pT4 tumors are generally larger, and it is more difficult to accurately determine the depth of invasion using conventional methods. Moreover, there is some overlap between the pT system and the Borrmann classification system in patients with advanced gastric cancer. Therefore, we examined the influence of our revised Borrmann classification in patients with pT3 and pT4 APGC, which revealed that r-Bor IV was an independent predictor of poor prognosis in all patients with APGC. In patients with infiltrative gastric cancer (pT3 and pT4a), r-Bor IV was still associated with significantly poorer survival than r-Bor III, and the magnitude of the survival difference was large enough to outweigh the prognostic value of pT status. Thus, a more aggressive postoperative adjuvant treatment strategy should be adopted for patients with pT3 or pT4a r-Bor IV.

This study has several limitations. First, we only included patients with advanced cancers who underwent radical surgery, and excluded patients with pT4b disease to more accurately evaluate the influence of LBVI status. However, we reviewed the patients' surgical records, and identified 105 patients who were diagnosed with sT4b disease (intraoperative identification of adjacent organ invasion), and only 10 patients who were postoperatively diagnosed with pT4b disease. Thus, we included sT4b as a covariate in the Cox regression model. Another limitation is that LBVI was identified based on routine histological H&E staining, and the tumor sections were examined at the largest specimen width which may have limited the sensitivity of LBVI detection.

In conclusion, APGC patients with LBVI had significantly shorter survival than patients without LBVI, although LBVI+ status was not an independent prognostic factor in the multivariate analysis. Our data indicate that LBVI status may help clarify the difference between Borrmann type III and IV tumors. Based on our revised system, we suggest that patients with r-Bor IV APGC should be treated the same as patients with standard Borrmann type IV APGC. Furthermore, in patients with pT3 and pT4a APGC, r-Bor IV could be used to guide prognostication and follow-up treatment.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Lymphatic and/or blood vessel invasion (LBVI) plays an important role in tumor cell dissemination and metastasis during tumor progression, which contributes to the poor prognosis of patients with gastric cancer.

Research motivation
-------------------

The Borrmann classification is generally assigned based on macroscopic examination of the tumor, although some Borrmann type III tumors have a similar appearance and prognosis to Borrmann type IV tumors, which has led to the term "limited Borrmann type IV". Previous studies have indicated that Borrmann type IV disease has a very poor prognosis.

Research objectives
-------------------

In this study, the authors aim to evaluate the prognostic significance of LBVI combined with the Borrmann type in advanced proximal gastric cancer (APGC).

Research methods
----------------

The clinicopathological and survival data of 440 patients with APGC who underwent curative surgery between 2005 and 2012 were retrospectively analyzed.

Research results
----------------

In these 440 patients, LBVI+ status was associated with Borrmann type IV, low histological grade, large tumor size, and advanced pT and pN status. The 5-year survival rate of LBVI+ patients was significantly lower than that of LBVI-- patients, although LBVI was not an independent prognostic factor in the multivariate analysis. No significant difference in the prognosis of patients with Borrmann type III/LBVI+ disease and patients with Borrmann type IV disease was observed. Therefore, we proposed a revised Borrmann type IV (r-Bor IV) as Borrmann type III plus LBVI+, and found that r-Bor IV was associated with poor prognosis in patients with APGC, which outweighed the prognostic significance of pT status.

Research conclusions
--------------------

LBVI status may help clarify the difference between Borrmann type III and IV tumors. Based on our revised classification, we suggest that patients with (r-Bor IV APGC should be treated the same as patients with standard Borrmann type IV APGC.

Research perspectives
---------------------

In patients with pT3 and pT4a APGC, r-Bor IV could be used to guide prognostication and follow-up treatment.
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